Lilly angles for arthritis blockbuster
Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis.
Pharmaceutical
Articles
Lilly wins FDA approval for plaque psoriasis drug
For Eli Lilly and Co., the approval rewards a decade-long effort to re-enter the biotech and autoimmune spaces that it helped pioneer in the 1980s but then abandoned in the 1990s.
Express Scripts leader wants Anthem to stay client despite $15B suit
Express Scripts Holding Co.’s incoming CEO is trying to keep its biggest customer after Anthem Inc. sued to recoup billions of dollars in what it called excess payments for drugs and threatened to end their relationship.
Pence signs anti-methamphetamine proposals into law
Pharmacists in Indiana will be able to limit how much cold medicine customers can buy under a measure Indiana Gov. Mike Pence signed into law Monday.
Anthem slaps lawsuit on Express Scripts over drug pricing
The insurer’s CEO said in January that Anthem should be reaping an addition $3 billion per year in savings on drugs from Express Scripts, which manages its pharmacy benefits.
Indiana House passes two bills to curb meth
Two measures aimed at to reducing methamphetamine production in Indiana are on their way to the governor's desk after receiving approval from the full House.
For Lilly’s Cialis, glory days are over
The erectile-dysfunction drug, made famous by a slew of quirky commercials, is facing performance issues of its own.
Teva closing in on $40B buy of Allergan generics unit
Teva’s acquisition will make it the world’s largest maker of generic medicines, giving it greater negotiating power with governments and private-health insurers.
Lawmakers zeroing in on anti-meth plan
Bills would let pharmacists require prescriptions for suspicious customers trying to buy cold medicines with pseudoephedrine. But some drug store chains fear putting their pharmacists in danger.
Kroger to offer anti-overdose drug without prescription
The supermarket chain will make naloxone available in its pharmacies across Ohio and northern Kentucky, a region hard-hit by deadly heroin.
Proposal for cold medicine prescriptions being scaled back
The new version of the Indiana bill would classify pseudoephedrine in a way that most consumers would be able to buy it, but pharmacists could require a prescription from suspicious customers.
UPDATE: Pharmacist consultation bill clears senate committee
Indiana pharmacists could get the legal right to refuse to sell a common cold medicine used to make methamphetamine to suspicious customers under a bill a Senate committee approved Tuesday.
Lilly’s 2016 sales, profit guidance falls short of predictions
Indianapolis-based Eli Lilly and Co., which has promised to return to growth after a half-decade of falling revenue, indicated that 2016 earnings might be below analysts’ estimates.
First-of-a-kind drug approvals continued rise in 2015
The rising figures reflect an industry-wide focus on drugs for rare and hard-to-treat diseases, which often come with streamlined reviews, extra patent protections and higher price tags.
Deal puts IU doctor’s research on path to market
A professor in the Indiana School of Medicine is hopeful that an antibiotic cocktail he invented will one day improve the lives of millions of people, thanks in part to the Indiana University Research and Technology Corp., formed in 1997 to make work done by IU faculty and researchers available for commercial development.
Lilly could pay $800M-plus in pact with drug-tech firm
The companies will work on coupling therapies from Lilly with technology from Halozyme Therapeutics that helps the body disperse and spread medicine.
FDA OKs once-a-day insulin that could be blockbuster for Lilly
The FDA said Wednesday it approved Basaglar based on data showing it is safe and effective and works similarly to Lantus, the world’s top-selling insulin.
Autism likelier when antidepressants taken during pregnancy
A new study says women who took a common class of antidepressants during the second and third trimesters were more than twice as likely than other women to have children who later developed autism.
Eli Lilly ends development of promising insulin drug
Eli Lilly said Friday that it decided to stop developing the insulin peglispro after learning that it would take more time and cost more than expected to understand a significant side effect.
Experts see big premium increases for Medicare drug plan
With time running out on open-enrollment season, many seniors are facing sharply higher costs for Medicare's popular prescription drug program after a long stretch of stable premiums.